Back to today’s briefing

Story perspectives

FDA May Fast-Track Enlicitide: LDL Cholesterol Slashed by 60%

2/5/2026

26 4

Summary

Story summary

Enlicitide lowers LDL cholesterol by up to 60% over six months in high-risk heart attack patients who struggle with statins.
The FDA is considering fast-tracking approval for enlicitide.
Enlicitide must be taken on an empty stomach.
Experts caution that it remains unclear whether the LDL reduction will lead to fewer heart attacks or strokes.
Merck is conducting a larger study with over 14,000 patients to assess long-term effects.

1 of 1

Story summary

Enlicitide lowers LDL cholesterol by up to 60% over six months in high-risk heart attack patients who struggle with statins.
The FDA is considering fast-tracking approval for enlicitide.
Enlicitide must be taken on an empty stomach.
Experts caution that it remains unclear whether the LDL reduction will lead to fewer heart attacks or strokes.
Merck is conducting a larger study with over 14,000 patients to assess long-term effects.